An Evaluation of Treatment Effect in Responder and Non-responder Patients with Nocturia Receiving SER120 Nasal Spray in 2 Phase III Clinical Studies

Research Type

Clinical

Abstract Category

Nocturia

Links
	Abstract 472
	Open Discussion ePosters Scientific Open Discussion Session 27
	Friday 16th September 2016
	12:40 - 12:45 (ePoster Station 1)
	ePoster Area
	Clinical Trial Nocturia Quality of Life (QoL) Voiding Dysfunction
	1. Vanderbilt University, 2. University of Pennsylvania, 3. Serenity Pharmaceuticals, 4. Allergan plc
Presenter
R Roger Dmochowski
Abstract PDF Edit Abstract Abstract Centre